Product Code: GDHC519DFR
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Lotronex (alosetron) is indicated for women with severe IBS-D who have chronic IBS, have had anatomic or biochemical abnormalities of the GI tract excluded, and have not responded adequately to conventional therapy. GlaxoSmithKline (GSK) initially introduced this product into the US market in February 2000. However, a few months later, in November 2000, the company decided to withdraw the drug due to it being linked with undesirable adverse effects, such as ischemic colitis (restricted blood flow to the colon), severe constipation, and three fatalities.
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lotronex including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lotronex for the top country from 2013 to 2023.
- Sales information covered for the US.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Lotronex performance.
- Obtain sales forecast for Lotronex from 2013-2023 in top country (the US).
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 2.1. Catalyst
- 2.2. Related Reports
3. Disease Overview
- 3.1. Etiology and Pathophysiology
- 3.1.1. Etiology
- 3.1.2. Pathophysiology
- 3.2. Classification
- 3.3. Symptoms
- 3.4. Prognosis
- 3.5. Quality of Life
4. Disease Management
- 4.1. Diagnosis and Treatment Overview
- 4.1.1. Diagnosis
- 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
- 4.1.3. Clinical Practice
5. Competitive Assessment
6. Lotronex (alosetron)
- 6.1. Overview
- 6.2. Efficacy
- 6.3. Safety
6.4. SWOT Analysis
- 7.1. Bibliography
- 7.2. Abbreviations
- 7.3. Methodology
- 7.4. Forecasting Methodology
- 7.4.1. Diagnosed IBS Patients
- 7.4.2. General Pricing Assumptions
- 7.4.3. Individual Drug Assumptions
- 7.4.4. Generic Erosion
- 7.5. Primary Research - KOLs Interviewed for This Report
- 7.6. Primary Research - Prescriber Survey
- 7.7. About the Authors
- 7.7.1. Analyst
- 7.7.2. Therapy Area Director
- 7.7.3. Global Head of Healthcare
- 7.8. About GlobalData
- 7.9. Disclaimer
List of Tables
- Table 1: Common Symptoms of IBS
- Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
- Table 3: Treatment Guidelines for IBS
- Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
- Table 5: Leading Branded Treatments for IBS, 2014
- Table 6: Product Profile - Lotronex
- Table 7: Safety of Lotronex - Most Frequently Reported Adverse Events
- Table 8: Lotronex SWOT Analysis, 2014
- Table 9: Global IBS Sales Forecasts ($m) for Lotronex, 2013-2023
- Table 10: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country
List of Figures
- Figure 1: Summary of Pharmacotherapies Used to Treat IBS